We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+5.45%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$180M
AUM Growth
+$35.3M
(+24%)
Cap. Flow
+$33.3M
Cap. Flow
% of AUM
18.49%
Top 10 Holdings %
Top 10 Hldgs %
21.58%
Holding
287
New
78
Increased
46
Reduced
73
Closed
55
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$4.54M |
| 2 |
Coherus Oncology
CHRS
|
+$3.29M |
| 3 |
Amylyx Pharmaceuticals
AMLX
|
+$2.71M |
| 4 |
Embecta
EMBC
|
+$2.55M |
| 5 |
Invesco S&P 500 Pure Value ETF
RPV
|
+$2.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$4.1M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$2.81M |
| 3 |
Invesco NASDAQ 100 ETF
QQQM
|
+$2.81M |
| 4 |
Innoviva
INVA
|
+$2.07M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$1.63M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.9% |
| 2 | Real Estate | 10.66% |
| 3 | Financials | 4.01% |
| 4 | Technology | 3.46% |
| 5 | Consumer Discretionary | 2.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KALV
51
DELISTED
KalVista Pharmaceuticals
KALV
| $1.22M | 0.67% |
+135,000
| New | +$1.24M |
|
52
Allient
ALNT
$1.49B
| $1.2M | 0.66% |
30,000
-5,000
| -14% | -$182K |
|
53
Acadia Pharmaceuticals
ACAD
$4.38B
| $1.2M | 0.66% |
50,000
| – | – |
|
|
VRNA
54
DELISTED
Verona Pharma
VRNA
| $1.16M | 0.65% |
55,000
| – | – |
|
55
Verastem
VSTM
$530M
| $1.12M | 0.62% |
+150,000
| New | +$1.04M |
|
56
Omnicell
OMCL
$2.09B
| $1.11M | 0.61% |
15,000
| – | – |
|
57
Alkermes
ALKS
$8.79B
| $1.1M | 0.61% |
35,000
-10,000
| -22% | -$303K |
|
|
DCPH
58
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $1.09M | 0.61% |
77,500
+5,000
| +7% | +$71.5K |
|
59
Synopsys
SNPS
$73.6B
| $1.09M | 0.6% |
2,500
| – | – |
|
60
Symbotic
SYM
$5.25B
| $1.07M | 0.59% |
+25,000
| New | +$821K |
|
61
Enact Holdings
ACT
$6.49B
| $1.06M | 0.59% |
42,367
+17,000
| +67% | +$415K |
|
62
Collegium Pharmaceutical
COLL
$1.17B
| $1.06M | 0.59% |
49,500
| – | – |
|
63
AeroVironment
AVAV
$7.2B
| $1.02M | 0.57% |
10,000
-5,000
| -33% | -$503K |
|
64
Mobileye
MBLY
$7.76B
| $961K | 0.53% |
25,000
| – | – |
|
|
RWT
65
Redwood Trust
RWT
$641M
| $934K | 0.52% |
146,593
| – | – |
|
66
SoundHound AI
SOUN
$2.73B
| $910K | 0.5% |
+200,000
| New | +$595K |
|
67
Welltower
WELL
$172B
| $895K | 0.5% |
11,059
| – | – |
|
68
argenx
ARGX
$53.8B
| $877K | 0.49% |
+2,250
| New | +$885K |
|
69
Crinetics Pharmaceuticals
CRNX
$8.88B
| $847K | 0.47% |
+47,000
| New | +$937K |
|
|
ONIT
70
Onity Group
ONIT
$344M
| $845K | 0.47% |
28,195
-7,423
| -21% | -$213K |
|
71
Viridian Therapeutics
VRDN
$1.99B
| $845K | 0.47% |
35,500
| – | – |
|
72
Stereotaxis
STXS
$154M
| $842K | 0.47% |
550,000
| – | – |
|
|
ITOS
73
DELISTED
iTeos Therapeutics
ITOS
| $834K | 0.46% |
63,000
| – | – |
|
74
iShares 3-7 Year Treasury Bond ETF
IEI
$18.2B
| $798K | 0.44% |
6,920
+2,225
| +47% | +$261K |
|
75
Annaly Capital Management
NLY
$16.9B
| $750K | 0.42% |
37,500
| – | – |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q2 2023 Portfolio in Review
As of Q2 2023, AlphaCentric Advisors held 287 positions worth $180M, up 24% from $145M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
AlphaCentric Advisors deployed $33.3M of net new capital in Q2 2023, opening 78 new positions and adding to 46 existing holdings. Its largest new stake was Embecta: 93,500 shares worth $2.02M.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 56% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was iShares 1-3 Year Treasury Bond ETF, an estimated $4.1M trimmed.
- AlphaCentric Advisors's largest Q2 2023 buy was Embecta: 93,500 shares worth $2.02M.
- AlphaCentric Advisors added most to Jazz Pharmaceuticals in Q2 2023, an estimated $4.54M increase.
- AlphaCentric Advisors's biggest Q2 2023 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $4.1M.
- AlphaCentric Advisors fully exited Invesco QQQ Trust in Q2 2023, selling an estimated $2.81M.
- AlphaCentric Advisors's ten largest holdings make up 22% of its $180M portfolio in Q2 2023.
- AlphaCentric Advisors opened 78 new positions and closed 55 in Q2 2023.
- AlphaCentric Advisors's portfolio value rose 24% quarter-over-quarter to $180M.
Based on AlphaCentric Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.